Who should not take PE-22-28?
Documented caution flags for PE-22-28 include active SSRI / SNRI / MAOI regimens and cardiac arrhythmia history. This is not exhaustive, and absence from this list is not a safety clearance. Anyone pregnant, nursing, or managing a serious medical condition should only consider it under a doctor's care, and safety data for PE-22-28 is limited.
Documented caution flags for PE-22-28
- Active SSRI / SNRI / MAOI regimens
- Cardiac arrhythmia history
- Pregnancy / nursing
Reported side effects to weigh
- Limited human safety data
- Theoretical effects on cardiac TREK-1 channels
References
- PE-22-28: a novel peptide for fast-acting antidepressant treatment — Mazella J et al., PLoS Biol, 2010
- Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity — Djillani A et al., Frontiers in Pharmacology, 2017
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on PE-22-28
Last updated 2026-06-15.